Investment Thesis
Insmed demonstrates strong revenue growth of 66.7% YoY, indicating product market traction, but is burning cash aggressively with -$226.2M free cash flow despite $306M in revenue, signaling fundamental profitability challenges. While the balance sheet is solid ($582.2M cash, 4.47x current ratio), the -50.1% operating margin and -$163.6M net loss create material downside risk unless the company can achieve near-term operational leverage.
Strengths
- Strong top-line growth of 66.7% YoY demonstrates product demand and market acceptance
- Solid balance sheet with $582.2M in cash and 0.78x debt/equity provides financial runway of ~2.5 years at current burn rate
- Excellent liquidity position (4.47x current ratio, 4.10x quick ratio) ensures short-term operational stability
- Reasonable gross margin of 30.7% suggests viable product economics at manufacturing level
Risks
- Severe operating margin of -50.1% with -$153.3M operating loss indicates fundamental cost structure misalignment that revenue growth is not offsetting
- Negative free cash flow of -$226.2M annually is unsustainable; company is depleting cash reserves despite revenue growth, creating existential risk if burn rate persists
- Negative interest coverage ratio of -1.8x shows company cannot service debt from operations; entirely dependent on cash reserves
- Pharmaceutical sector inherently risky; path to profitability unclear, and revenue growth may decelerate while fixed costs remain high
- If revenue growth moderates while operating losses persist, cash runway shrinks rapidly, forcing dilutive financing or restructuring
Key Metrics to Watch
- Operating margin trend - must move toward positive territory; even slight improvement to -30% would be concerning but directional signal
- Free cash flow trajectory - critical to see cash burn decline toward breakeven; current -$226.2M rate is unsustainable
- Cash balance depletion rate - monitor quarterly cash position relative to burn; risk of adequacy within 18-24 months if trends persist
- Gross margin sustainability - confirm 30.7% margin holds as revenue scales; margin compression would indicate pricing pressure or manufacturing inefficiency
Financial Metrics
Revenue
306.0M
Net Income
-163.6M
EPS (Diluted)
$-0.76
Free Cash Flow
-226.2M
Total Assets
2.1B
Cash
582.2M
Profitability Ratios
Gross Margin
30.7%
Operating Margin
-50.1%
Net Margin
-53.5%
ROE
-23.2%
ROA
-7.9%
FCF Margin
-73.9%
Balance Sheet & Liquidity
Current Ratio
4.47x
Quick Ratio
4.10x
Debt/Equity
0.78x
Debt/Assets
66.0%
Interest Coverage
-1.83x
Long-term Debt
546.8M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T11:16:30.549516 |
Data as of: 2026-03-31 |
Powered by Claude AI